Press Release
<p>WIN A $10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD</p>
<p><strong>Ferring Pharmaceuticals Announces <i>My Little Miracle</i> Essay Contest</strong> </p>
<table><tr><td valign="top"><b>Contact:</b></td><td width="20" valign="top"></td><td>Kelly Laban<br>Kovak-Likly
Communications<br>(203)762-8833 or KLaban@KLCpr.com</td></tr></table>
<p>If you are a mom who has successfully given birth using Ferring Pharmaceuticals’
infertility products, you can win a $10,000 education fund or one of 11 other
prizes to support your child’s future. To be eligible, all you need to do is write
a brief essay on your journey to achieve parenthood and its impact on your life. </p>
<p>Ferring’s <i>My Little Miracle</i> contest is open to women who have been successfully<br>
treated with Bravelle<sup><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>®</sup></font></sup>
(urofollitropin for injection), Repronex<sup><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>®</sup></font></sup>
(menotropins
for injection, USP) or a combination of both. The contest celebrates the miracles of their
children’s births and continues Ferring’s tradition of providing value to their patients
through affordable fertility treatments by offering education funds for the winners’
children. </p>
<p>Ferring is also awarding a $5,000 education fund for the runner up and 10<br>
honorable mention winners will each receive $1,000. All 12 winners will be featured
in Ferring’s 2005 <i>Year of Miracles</i> calendar. </p>
<p>Essays should not exceed 400 words, must be written in English, include the<br>
entrant’s name, address, phone number, and age, as well as the child(ren)’s name
and age(s) and be submitted with a contest application and labeled photo. Entries
must be postmarked or e-mailed by September 30, 2004. Winners will be announced
at the 60th Annual Meeting of the American Society for Reproductive Medicine,
October 16 - 20, 2004 at the Pennsylvania Convention Center in Philadelphia, PA. </p>
<p>For more details and a contest application visit <a href="http://www.ferringfertility.com" target="_blank">www.ferringfertility.com</a>,<br>
<a href="http://www.ferringusa.com" target="_blank">www.ferringusa.com</a> or
call (203) 762-8833 and ask for the <i>My Little Miracle</i> Essay Contest representative. </p>
<p>Repronex<sup><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>®</sup></font></sup>
and Bravelle<sup><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>®</sup></font></sup>
, like all gonadotropins, are potent substances
capable of causing mild to severe adverse reactions, including OHSS (incidence of 3.5%
and 6.8%, respectively), with or without pulmonary or vascular complications, in women
undergoing therapy for infertility. </p>
<p>Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader
in naturally occurring protein hormones. Only physicians thoroughly familiar with
infertility treatment, including the risk of multiple births and adverse reactions, should
prescribe these medications. Like other products for ovarian stimulation, treatment with
Repronex<sup><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>®</sup></font></sup>
and/or Bravelle<sup><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>®</sup></font></sup>
may result in multiple gestations. </p>
EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used in people who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.
Important Safety Information
You should not receive this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products. You should not have an injection into the knee if you have a knee joint infection or if you have skin disease or infection around the injection site.
EUFLEXXA is only for injection into the knee performed by a qualified doctor. After you receive this injection you may need to avoid activities such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour). The safety and effectiveness of repeat treatment cycles of EUFLEXXA have not been established. The safety and effectiveness of EUFLEXXA have not been shown in people under 18 years of age.
Side effects sometimes seen when EUFLEXXA is injected into the knee joint were pain, swelling, skin irritation, and tenderness and these were generally mild and did not last long.
Please see Full Prescribing Information.
Please see Important Information for Patients.
Patient Treatment Information
PLEASE CONSULT WITH YOUR DOCTOR, OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL BEFORE USING ANY PRODUCT DISCUSSED WITHIN THIS WEB SITE.
This website is intended only for US residents.
Euflexxa® is a registered trademark of Ferring Pharmaceuticals Inc.
